Incyte registers Phase 2 trial of INCA33890 in MRD-positive colorectal cancer
Incyte has posted a new Phase 2 study testing INCA33890 in patients with ctDNA-positive colorectal cancer following surgery and chemotherapy.
Incyte's only new registry item this week is a single Phase 2 trial listing.
- Incyte registered "NEXERA-204" (NCT07823322), a Phase 2 study of INCA33890 in the treatment of circulating tumor DNA-positive stage II/III microsatellite stable colorectal cancer after curative resection and chemotherapy.1 The trial is not yet recruiting, with an estimated start date of October 26, 2026 and estimated primary completion on May 14, 2029.1 It plans to enroll 40 participants, using a single-group design.1 The primary outcome is ctDNA clearance at 3 months, defined as ctDNA positive at baseline changing to ctDNA negative at 3 months.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.